Sumitomo Mitsui Trust Holdings Inc. Trims Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Sumitomo Mitsui Trust Holdings Inc. trimmed its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 0.5% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 295,279 shares of the biopharmaceutical company’s stock after selling 1,421 shares during the period. Sumitomo Mitsui Trust Holdings Inc.’s holdings in Alnylam Pharmaceuticals were worth $56,519,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ALNY. Aquila Investment Management LLC grew its holdings in shares of Alnylam Pharmaceuticals by 50.0% during the fourth quarter. Aquila Investment Management LLC now owns 3,000 shares of the biopharmaceutical company’s stock worth $574,000 after purchasing an additional 1,000 shares during the last quarter. Simplicity Solutions LLC grew its stake in Alnylam Pharmaceuticals by 23.1% during the 4th quarter. Simplicity Solutions LLC now owns 1,997 shares of the biopharmaceutical company’s stock worth $382,000 after buying an additional 375 shares during the last quarter. Moody Aldrich Partners LLC increased its position in Alnylam Pharmaceuticals by 43.9% during the fourth quarter. Moody Aldrich Partners LLC now owns 3,285 shares of the biopharmaceutical company’s stock worth $629,000 after buying an additional 1,002 shares during the period. Sequoia Financial Advisors LLC lifted its stake in Alnylam Pharmaceuticals by 175.2% in the fourth quarter. Sequoia Financial Advisors LLC now owns 7,714 shares of the biopharmaceutical company’s stock valued at $1,477,000 after buying an additional 4,911 shares during the last quarter. Finally, Bleakley Financial Group LLC lifted its stake in Alnylam Pharmaceuticals by 24.9% in the fourth quarter. Bleakley Financial Group LLC now owns 2,026 shares of the biopharmaceutical company’s stock valued at $388,000 after buying an additional 404 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $145.16 on Friday. The stock’s 50 day moving average price is $152.07 and its 200 day moving average price is $167.03. The company has a market cap of $18.28 billion, a PE ratio of -40.78 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 1-year low of $143.52 and a 1-year high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, topping the consensus estimate of ($1.20) by $0.10. The company had revenue of $439.72 million for the quarter, compared to analysts’ expectations of $439.38 million. Alnylam Pharmaceuticals’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.68) earnings per share. On average, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -4.54 EPS for the current fiscal year.

Analyst Ratings Changes

ALNY has been the topic of a number of recent research reports. JPMorgan Chase & Co. lifted their target price on shares of Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the company a “neutral” rating in a report on Thursday, February 1st. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Monday, April 8th. StockNews.com raised Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, April 13th. Chardan Capital dropped their price target on Alnylam Pharmaceuticals from $250.00 to $225.00 and set a “buy” rating on the stock in a research report on Friday, February 16th. Finally, Wells Fargo & Company decreased their price objective on Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating for the company in a research report on Friday, February 16th. Eight research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $216.12.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.